Literature DB >> 11535988

The role of bone marrow transplantation in acute promyelocytic leukemia.

C Nabhan1, J Mehta, M S Tallman.   

Abstract

Acute promyelocytic leukemia (APL) is characterized by a specific gene rearrangement and the generation of the PML-RARalpha fusion transcript which results from a translocation between chromosomes 15 and 17. Targeted therapy with all-trans retinoic acid (ATRA) and anthracycline-based chemotherapy results in an apparent cure in 70-80% of patients. Both allogeneic (ALLO) and autologous (AUTO) hematopoietic stem cell transplantation (HSCT) are effective in acute myeloid leukemia (AML), but their role in APL is not clear given the excellent outcome with ATRA and chemotherapy. Several retrospective studies have analyzed the outcome of patients undergoing AUTO or ALLO-HSCT in first (CR1) or second (CR2) complete remission. Most of these studies have shown significant transplant-related mortality (TRM) with ALLO-HSCT, but a reduction in relapse rate compared with AUTO-HSCT. The high TRM with ALLO-HSCT and the excellent outcome with ATRA and chemotherapy do not justify recommending this procedure for the majority of patients in CR1. The role of AUTO-HSCT in CR1 also is unclear. A small subset of patients at high risk of relapse, possibly identifiable by a high white blood cell count at presentation may benefit from HSCT. Most patients with relapsed disease achieve CR2 with ATRA, arsenic trioxide, or combination therapy. However, it is not known if these responses are sustained or if consolidation with HSCT has a place in this setting. The outcome of AUTO-HSCT in CR2 using stem cells that are negative for PML-RARalpha is excellent. It is unclear whether ALLO-HSCT from an HLA-identical sibling is superior to AUTO-HSCT with PML-RARalpha-negative cells in CR2 since the former would be associated with graft-versus-leukemia effects and the latter with lower TRM. Alternatively, arsenic trioxide or re-treatment with ATRA, followed by intensive chemotherapy may also be effective. A randomized prospective clinical trial, or a retrospective analysis of the available data would be useful in answering this critical question.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11535988     DOI: 10.1038/sj.bmt.1703119

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  7 in total

Review 1.  Autologous stem cell transplantation in hematological malignancies.

Authors:  Norbert-Claude Gorin
Journal:  Springer Semin Immunopathol       Date:  2004-10-07

2.  Arsenic trioxide therapy in relapsed or refractory Japanese patients with acute promyelocytic leukemia: updated outcomes of the phase II study and postremission therapies.

Authors:  Kazuyuki Shigeno; Kensuke Naito; Naohi Sahara; Miki Kobayashi; Satoki Nakamura; Sinya Fujisawa; Kaori Shinjo; Akihiro Takeshita; Ryuzo Ohno; Kazunori Ohnishi
Journal:  Int J Hematol       Date:  2005-10       Impact factor: 2.490

3.  Autologous transplant remains the preferred therapy for relapsed APL in CR2.

Authors:  C Ganzel; V Mathews; K Alimoghaddam; A Ghavamzadeh; D Kuk; S Devlin; H Wang; M-J Zhang; D Weisdorf; D Douer; J M Rowe; E Polge; J Esteve; A Nagler; M Mohty; M S Tallman
Journal:  Bone Marrow Transplant       Date:  2016-04-18       Impact factor: 5.483

Review 4.  New advances in the treatment of acute promyelocytic leukemia.

Authors:  Dan Douer
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

Review 5.  Management of acute promyelocytic leukemia.

Authors:  Martin S Tallman; Chadi Nabhan
Journal:  Curr Oncol Rep       Date:  2002-09       Impact factor: 5.075

Review 6.  Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome.

Authors:  Jason A Coppell; Paul G Richardson; Robert Soiffer; Paul L Martin; Nancy A Kernan; Allen Chen; Eva Guinan; Georgia Vogelsang; Amrita Krishnan; Sergio Giralt; Carolyn Revta; Nicole A Carreau; Massimo Iacobelli; Enric Carreras; Tapani Ruutu; Tiziano Barbui; Joseph H Antin; Dietger Niederwieser
Journal:  Biol Blood Marrow Transplant       Date:  2009-09-18       Impact factor: 5.742

7.  Autologous is superior to allogeneic hematopoietic cell transplantation for acute promyelocytic leukemia in second complete remission.

Authors:  Jennifer L Holter Chakrabarty; Morel Rubinger; Jennifer Le-Rademacher; Hai-Lin Wang; Andrew Grigg; George B Selby; Jeffrey Szer; Jacob M Rowe; Daniel J Weisdorf; Martin S Tallman
Journal:  Biol Blood Marrow Transplant       Date:  2014-03-30       Impact factor: 5.742

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.